Close
FDA’s electronic Submission Template and Resource, or eSTAR, has changed how many medical device submissions are organized and prepared. But sponsors should be careful not to confuse submission structure with submission readiness.
FDA describes eSTAR as an interactive PDF designed to guide applicants through preparation of a comprehensive medical device submission and provide a standardized format that aligns with FDA review processes. That structure is valuable. But eSTAR cannot create evidence that was never generated. It cannot resolve an unclear intended use. And it cannot repair a clinical-development decision that should have been addressed months or years earlier.
FDA updated the eSTAR program in June 2026.
The IVD and non-IVD eSTAR templates now incorporate content from FDA’s May 2026 Human Factors Content Guidance, effective August 1, 2026. FDA also expanded voluntary use of the Early Submission Requests eSTAR, known as PreSTAR, to additional Q-Submission types including Submission Issue Requests, Informational Meetings, Study Risk Determinations, PMA Day 100 Meetings and Accessory Classification Requests.
These changes reinforce the importance of structured regulatory interaction and evidence preparation. But they also make inconsistencies easier to expose.
Think of eSTAR as the architecture through which information is presented. The underlying evidence still needs to exist. Before submission assembly begins, sponsors should already have alignment across:
If those components were developed independently, the submission may reveal inconsistencies.
For example, the population described in clinical evidence should make sense for the intended use. The performance claims should be supported by the analyses. The risk documentation should correspond with the device configuration being submitted. The human factors evidence should reflect the intended users, uses and use environments.
One of the most useful ways to evaluate readiness is to ask whether the sponsor can trace:
Traceability chain
Claim → Evidence → Analysis → Conclusion → Submission section.
If a claim appears in labeling but the underlying study does not clearly support it, the issue is not primarily an eSTAR problem. It is an evidence problem.
Similarly, if risk-management documentation identifies a potential harm but the relevant clinical or usability evidence cannot be connected to the corresponding risk-control strategy, the regulatory story may be incomplete.
Traceability is therefore much more than document organization. It is evidence coherence.
An unresolved evidence decision during development often becomes a question during regulatory review.
Common examples include:
The earlier these questions are addressed, the easier it becomes to design the study and evidence program around them. Waiting until eSTAR assembly is usually too late to fix a foundational clinical evidence gap efficiently.
For development questions where FDA feedback could materially affect the evidence program, sponsors may benefit from engaging through the appropriate Q-Submission pathway before the final marketing submission.
A productive FDA interaction should begin with defined questions and a well-supported sponsor proposal.
The team should understand the regulatory objective, current evidence, unresolved questions and what specific feedback is being requested.
This is fundamentally different from asking FDA to create the development strategy. Regulatory interaction works best when the sponsor brings a thoughtful evidence plan that FDA can evaluate.
Submission readiness should therefore begin during clinical development.
Stronger sequence
Define intended use → map evidence gaps → design the evidence strategy → generate the data → maintain traceability → assess submission readiness → assemble eSTAR.
Not: Run studies → open eSTAR → discover what is missing.
This approach can reduce late-stage rework, conflicting documentation and avoidable regulatory questions.
FDA’s Quality Management System Regulation became effective in 2026 and incorporates ISO 13485:2016 by reference into the device quality-system framework.
That makes disciplined documentation and lifecycle alignment especially important.
Submission materials should be consistent with the product-development and quality records that support them.
The practical message is straightforward: the submission file should be the output of a controlled evidence-generation process – not the place where that process begins.
Dynamill Research supports medical device and IVD sponsors across FDA regulatory strategy, Q-Submission planning, clinical evidence development, evidence-gap assessment, clinical study planning, and FDA eSTAR submission readiness. Successful medical device submission readiness begins well before the eSTAR template is opened. Sponsors need to ensure that their regulatory strategy, clinical evidence, intended use, performance claims, risk documentation, and supporting analyses are aligned before final submission assembly begins.
Dynamill helps sponsors identify potential FDA submission gaps earlier in development, when there is still an opportunity to address them efficiently. This can include reviewing the relationship between the intended use, target population, clinical or performance claims, supporting evidence, risk-management documentation, human factors information, and statistical analyses that will ultimately support the marketing submission. For programs with unresolved development questions, Dynamill can also support FDA Q-Submission and Pre-Submission planning. Questions related to study design, endpoints, comparator strategy, patient population, analytical methods, clinical evidence requirements, or regulatory pathway can often be more effectively addressed before the final eSTAR submission is prepared.
From a clinical-development perspective, Dynamill helps connect FDA regulatory strategy with clinical execution. Each study should have a defined purpose within the broader evidence roadmap, including the claims it is expected to support and the regulatory decision it is intended to inform.
As the program progresses, Dynamill can help sponsors evaluate evidence traceability across the submission:
Intended Use → Clinical or Performance Claim → Supporting Evidence → Analysis → Conclusion → eSTAR Submission Section
Strong traceability can reduce inconsistencies across the submission, strengthen the regulatory narrative, and make it easier to demonstrate how the evidence supports the proposed device claims. For sponsors preparing an FDA eSTAR medical device submission, Dynamill can provide submission-readiness support before final assembly by helping assess whether the required evidence, documentation, and analyses are sufficiently developed and aligned with the planned regulatory pathway. Our objective is to help sponsors approach FDA submission with fewer unresolved evidence gaps, stronger clinical and regulatory alignment, and a more coherent and defensible submission package.
Rather than treating eSTAR preparation as a final documentation exercise, Dynamill helps sponsors build FDA submission readiness into the clinical-development strategy from the beginning.